Abstract
Background: The ongoing Coronavirus Disease 2019 (COVID-19) epidemic represents an unprecedented global health challenge. Many COVID-19 symptoms are similar to symptoms that can occur in other infections. Malaria should always be considered in patients with SARS-CoV-2 infection returning from endemic areas.
Case presentation: We present the first case of multisystem inflammatory syndrome (MIS-C) and Plasmodium vivax-falciparum and SARS-CoV2 coinfection in children. Despite clearance of parassitaemia and a negative COVID-19 nasopharyngeal PCR, the patient’s clinical conditions worsened. The World Health Organization (WHO) criteria were used to make the diagnosis of MIS-C. Treatment with intravenous immunoglobulins and methylprednisolone was effective.
Conclusions: This case emphasizes the importance of considering malaria diagnosis in patients returning from endemic areas, even in the COVID 19 era. Malaria and SARS-CoV2 co-infection may increase the risk of MIS-C, for which early detection is critical for proper management.
Keywords: COVID-19; Case report; Malaria; Multisystem inflammatory syndrome; SARS CoV2.
【저자키워드】 COVID-19, Case report, malaria, Multisystem inflammatory syndrome, SARS CoV2, 【초록키워드】 Methylprednisolone, coronavirus disease, Coronavirus disease 2019, Intravenous immunoglobulin, SARS-CoV2, SARS-COV-2 infection, children, Infection, Diagnosis, risk, Symptom, MIS-C, malaria, COVID 19, Epidemic, Health, infections, PCR, nasopharyngeal, management, Early detection, Patient, Co-infection, WHO, Critical, Endemic, Inflammatory, criteria, COVID-19 symptom, Health Organization, Plasmodium vivax, World Health Organization, syndrome, clinical condition, Plasmodium, clearance, effective, the patient, were used, occur, patients with SARS-CoV-2, worsened, 【제목키워드】 Co-infection, P. falciparum,